Protalix BioTherapeutics, Inc.
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2021 | $79.7M | $73.7M | $39.0M |
| FY2022 | $66.4M | $55.8M | $17.1M |
| FY2023 | $50.9M | $84.4M | $23.6M |
| FY2024 | $30.2M | $73.4M | $19.8M |
| FY2025 | $34.1M | $82.3M | $14.7M |
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2021 | $79.7M | $73.7M | $39.0M |
| FY2022 | $66.4M | $55.8M | $17.1M |
| FY2023 | $50.9M | $84.4M | $23.6M |
| FY2024 | $30.2M | $73.4M | $19.8M |
| FY2025 | $34.1M | $82.3M | $14.7M |